Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising therapeutic strategy in the treatment of breast cancer, particularly for patients with hereditary BRCA1 and BRCA2 mutations [95]. This evidence concerns the gene PARP1 and breast carcinoma.